Valuation: Evotec SE

Capitalization 156.2Cr 164.11Cr 144.76Cr 128.75Cr 232.42Cr 14TCr 257.58Cr 1.8TCr 665.4Cr 5.72TCr 616.14Cr 602.84Cr 25TCr P/E ratio 2024 *
-11.3x
P/E ratio 2025 * -39.8x
Enterprise value 169.06Cr 177.62Cr 156.67Cr 139.35Cr 251.55Cr 15TCr 278.78Cr 1.95TCr 720.18Cr 6.19TCr 666.85Cr 652.47Cr 27TCr EV / Sales 2024 *
2.1x
EV / Sales 2025 * 1.95x
Free-Float
-
Yield 2024 *
-
Yield 2025 * -
More valuation ratios * Estimated data
Dynamic Chart
1 day-0.45%
1 week-1.34%
Current month-0.23%
1 month+15.39%
3 months+47.69%
6 months-0.23%
Current year-58.60%
More quotes
1 week
8.53
Extreme 8.53
9.12
1 month
7.98
Extreme 7.98
10.62
Current year
5.06
Extreme 5.06
21.42
1 year
5.06
Extreme 5.06
21.69
3 years
5.06
Extreme 5.06
44.94
5 years
5.06
Extreme 5.06
45.83
10 years
2.86
Extreme 2.864
45.83
More quotes
Director TitleAgeSince
Chief Executive Officer - 01/07/2024
Director of Finance/CFO 51 01/04/2023
Chief Operating Officer 54 01/01/2019
Manager TitleAgeSince
Chairman 64 15/06/2021
Director/Board Member 56 19/06/2019
Director/Board Member 62 01/06/2021
More insiders
Add to a list
Change 5d. change 1-year change 3-years change Capi. ($)
-0.45%-1.34%-51.91%-79.08%166.01Cr
+0.85%-1.06%+58.93%-30.68%4.27TCr
-1.57%+0.70%-5.61%-24.51%3.75TCr
+4.00%-1.35%+8.59%-8.45%2.53TCr
-1.49%+1.12%-20.74%-21.07%1.81TCr
-9.07%-6.21%-48.32%-84.75%1.76TCr
-1.30%-2.13%+49.90%+93.67%1.64TCr
-0.36%+1.45%+12.90%-34.39%1.23TCr
-2.92%-0.12%+20.75%+65.72%1.09TCr
-2.33%-2.09%-3.62%-44.81%1.03TCr
Average -1.46%+0.56%+2.09%-16.84% 1.93TCr
Weighted average by Cap. -0.99%+0.56%+12.35%-15.97%
See all sector performances

Financials

2024 *2025 *
Net sales 80Cr 85Cr 75Cr 66Cr 119.74Cr 7.18TCr 132.7Cr 928.66Cr 342.82Cr 2.95TCr 317.43Cr 310.58Cr 13TCr 90Cr 95Cr 84Cr 74Cr 134.23Cr 8.04TCr 148.75Cr 1.04TCr 384.27Cr 3.3TCr 355.82Cr 348.14Cr 14TCr
Net income -14Cr -15Cr -13Cr -12Cr -21Cr -1.28TCr -24Cr -166.23Cr -61Cr -527.37Cr -57Cr -56Cr -2.3TCr -3.8Cr -4Cr -3.53Cr -3.14Cr -5.66Cr -339.23Cr -6.27Cr -44Cr -16Cr -139.29Cr -15Cr -15Cr -607.85Cr
Net Debt 13Cr 14Cr 12Cr 11Cr 19Cr 1.15TCr 21Cr 148.38Cr 55Cr 470.74Cr 51Cr 50Cr 2.05TCr 19Cr 20Cr 18Cr 16Cr 29Cr 1.72TCr 32Cr 222.36Cr 82Cr 705.46Cr 76Cr 74Cr 3.08TCr
More financial data * Estimated data
Logo Evotec SE
Evotec SE is a Germany-based drug discovery and development company. The company is engaged in development of new pharmaceutical products through research alliances and development partnerships with pharmaceutical and biotechnology companies, academic institutions, patient organizations and venture capital companies. The drug discovery solutions are provided in the form of fee-for-service work, integrated drug discovery alliances, development partnerships, licensing of drug candidates and consulting arrangements. Evotec SE operates in a number of areas, including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases and fibrosis. Its pipeline covers a range of therapeutic areas, such as CNS Insomnia, Chronic cough, immunology & inflammation, women’s health endometriosis, nephrology, dermatological diseases, fibrotic disease and antiviral, among others.
Employees
5,007
More about the company
Date Price Change Volume
10/24/10 8.810 -0.45% 1,555,984
09/24/09 8.850 +0.91% 788,299
06/24/06 8.770 -1.79% 587,050
05/24/05 8.930 +2.64% 766,088
04/24/04 8.700 +1.34% 1,172,656

Delayed Quote Xetra, December 10, 2024 at 10:05 pm IST

More quotes
Trading Rating
Investor Rating
ESG Refinitiv
A-
surperformance-ratings-light-chart EVOTEC-SEMore Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
8
Last Close Price
8.810EUR
Average target price
11.04EUR
Spread / Average Target
+25.28%
Consensus

Quarterly revenue - Rate of surprise